AIDX

20/20 Biolabs Inc

Feb 19 • 04:00PM ET

23.85

-26.15 -52.30 %

Healthcare • Diagnostics & Research • USA • NASD

Feb 19, 9:07 AM20/20 BioLabs begins trading on Nasdaq under ticker AIDX and announces a contingent financing agreement with an institutional investor for up to $40 million, with an initial $5 million tranche expected to close today.

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	-	Perf Week	-
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	- -	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	- -	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	32.00	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	0.00%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	0.00%	Rel Volume	-	Prev Close	50.00
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	0.00%	Avg Volume	-	Price	23.85
IPO	Feb 19, 2026	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	35,415	Change	-52.30%

Feb-19-26 09:00AM

20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth

(GlobeNewswire)

open in yahoo | open in reuters | open in marketwatch | open in google

AIDX

20/20 Biolabs Inc

Upgrade your FINVIZ experience